Evidence map›Paper›PMID 41792583›Full record

ReviewAAPS PharmSciTech2026

Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and Permeation Enhancement.

Anushree Nagaraj, Ali Seyfoddin

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anushree NagarajSchool of Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand.
Ali SeyfoddinSchool of Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand. ali.seyfoddin@aut.ac.nz.ORCID http://orcid.org/0000-0003-4343-9905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) have garnered significant interest for their broad-spectrum pharmacological activity in managing chronic pain, neurological disorders, and cancer-associated symptoms. Despite their therapeutic promise, clinical translation remains hindered by poor aqueous solubility, extensive first-pass metabolism, and inconsistent systemic exposure following oral administration. Oral mucosal drug delivery systems offer a viable alternative by enabling transmucosal absorption, bypassing hepatic metabolism, and facilitating both rapid and sustained drug release. This review examines the evolution and design of oral mucosal dosage forms, including fast-dissolving films, mucoadhesive matrices, in situ gels, and particulate systems and highlights the critical role of formulation strategies in enhancing cannabinoid bioavailability. Fabrication techniques such as solvent casting, hot melt extrusion, and emerging 3D printing methods are also discussed, with a focus on their potential to enable personalized dosage forms. Furthermore, the integration of permeation enhancers like terpenes, and novel systems such as inclusion complexes and lipid-based carriers, presents new opportunities for improving the solubility and stability of lipophilic cannabinoids. Together, these innovations provide a framework for the development of stable, effective, and patient-centric oral mucosal cannabinoid delivery platforms with improved pharmacokinetic and therapeutic profiles.

Indexed as

CannabinoidsDrug Delivery SystemsMouth MucosaAdministration, OralAnimalsBiological AvailabilityCannabidiolChemistry, PharmaceuticalDelayed-Action PreparationsDronabinolDrug CarriersDrug CompoundingHumansOral Mucosal AbsorptionPermeabilitySolubilityCannabidiolCannabinoidsDelayed-Action PreparationsDronabinolDrug Carrierscannabidiol (CBD)formulation strategiesoral mucosal deliverysustained releasetetrahydrocannabinol (THC)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.